Skip to Content
Webcast: Crinetics Pharmaceuticals Corporate Update

Event Date: Crinetics Pharmaceuticals will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.

Read More
Webcast: Crinetics Pharmaceuticals Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Event Date: Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time.

Read More
Webcast: Crinetics to Report Fourth Quarter and Full Year 2025 Financial Results

Event Date: Event Date: February 26, 2026

Read More
Crinetics to Participate in TD Cowen 46 Annual Health Care Conference

Event Date: Event Date: March 4, 2026

Read More
Webcast: Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results

Event Date: Crinetics company management will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.

Read More
FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Event Date: Crinetics will host an investor conference call on September 25, at 6:00 pm Eastern Time to discuss the FDA approval of PALSONIFY. Live & Archived Webcast: https://events.q4inc.com/attendee/443074040 Dial-in Details: Domestic: 1-833-470-1428International: 1-646-844-6383Conference ID: 120796

Read More
Crinetics Pharmaceuticals 2025 R&D Day

Event Date: June 26, 2025

Read More